Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PE-A 5% in Acute-On-Chronic Liver Failure at High Risk of Hospital Mortality
2022-502187-20-00Phase 3Completed
- Sponsor
- Instituto Grifols
- Start
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 3, randomised trial of albumin (human) in acute-on-chronic liver failure (ACLF) and Cirrhosis (2 arms), sponsored by Instituto Grifols. Primary endpoint: 90-day overall survival. Started Feb 2024; status: completed.
02
Drugs
albumin (human)
03
Conditions
acute-on-chronic liver failure (ACLF)Cirrhosis
Beyond the preview
Go deeper on 2022-502187-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502187-20-00.